EE415 Cost Utility Analysis of Ocrelizumab Versus Fingolimod in Relapsing Remitting Multiple Sclerosis Patients in Egypt from Payor Perspective
Dec 1, 2022, 00:00
10.1016/j.jval.2022.09.661
https://www.valueinhealthjournal.com/article/S1098-3015(22)02865-0/fulltext
Title :
EE415 Cost Utility Analysis of Ocrelizumab Versus Fingolimod in Relapsing Remitting Multiple Sclerosis Patients in Egypt from Payor Perspective
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)02865-0&doi=10.1016/j.jval.2022.09.661
First page :
Section Title :
Open access? :
No
Section Order :
10198